This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elad, Y. Search for Related Content PubMed PubMed Citation Articles by Elad, Y.

CLINICAL STUDY: INTERVENTIONAL CARDIOLOGY

Primary angioplasty and selection bias inpatients presenting late (>12 h) after onset of chest pain and ST elevation myocardial infarction

Yaron Elad, MD^*, William J. French, MD, FACC^*,*, David M. Shavelle, MD, Lori S. Parsons, BS, Mark J. Sada, MD, FACC^*, Nathan R. Every, MD, MPH, FACC Participants in the National Registry of Myocardial Infarction 2

^* Saint John’s Cardiovascular Research Center, Division of Cardiology, Harbor-UCLA Medical Center, Torrance, California, USA
Division of Cardiology, University of Washington, Puget Sound Veterans Affairs Medical Center, Seattle, Washington, USA
Ovation Research Group, Seattle, Washington, USA

Manuscript received June 26, 2001; revised manuscript received November 21, 2001, accepted December 11, 2001.

^* Reprint requests and correspondence: Dr. William J. French, Division of Cardiology, Box 405, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, California 90509 USA.
wjfrench{at}ucla.edu

OBJECTIVES: This study was designed to compare the in-hospital outcome of patients presenting with >12 h from onset of chest pain and acute ST elevation myocardial infarction (AMI) who received either immediate invasive or conservative therapy.

BACKGROUND: The benefits of fibrinolytic therapy diminish in patients presenting with AMI and onset of chest pain >12 h. Primary angioplasty has been suggested as a possible treatment for such patients, but they have been excluded from most trials of primary angioplasty. It remains unclear if an invasive treatment strategy is beneficial to these patients.

METHODS: Patients presenting with >12 h of chest pain and AMI were identified from the National Registry of Myocardial Infarction 2 database. Patients receiving invasive therapy <6 h after hospital admission were compared with those receiving conservative therapy. Short-term outcomes were compared on the basis of the initial therapy received. To help control for baseline differences in the groups, patients were matched with controls by propensity score methodology.

RESULTS: On preliminary analysis, in-hospital outcome was improved in terms of recurrent ischemia, angina, myocardial infarction and mortality in patients receiving initial invasive therapy (odds ratio [OR] = 0.67; 95% confidence interval [CI] 0.49 to 0.92 for mortality). After matching by propensity score, the mortality benefit persisted on bivariate analysis (3.5% vs. 5.0%, p = 0.036), though on multivariate analysis, only a non-significant but strong trend toward decreased mortality remained (OR = 0.73; 95% CI 0.53 to 1.01).

CONCLUSIONS: Patients receiving early invasive therapy had lower risk features on presentation. Selection bias may play an important role in choosing these patients’ course of treatment and their subsequent outcomes. Certain patients presenting with AMI and duration of chest pain >12 h may benefit from early invasive therapy. These patients could be characterized in a randomized trial.

Abbreviations and Acronyms   GUSTO   AMI   acute ST elevation myocardial infarction   CABG   coronary artery bypass grafting   CHF   congestive heart failure   CI   confidence interval   CK   creatine kinase   ECG   electrocardiogram   GUSTO   Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries   MI   myocardial infarction   NRMI   National Registry of Myocardial Infarction   OR   odds ratio   PAMI   Primary Angioplasty in Myocardial Infarction   PTCA   percutaneous transluminal coronary angioplasty   TIMI   Thrombolysis In Myocardial Infarction

This article has been cited by other articles:

				V. Menon, C. A. Pearte, C. E. Buller, Ph.G. Steg, S. A. Forman, H. D. White, P. N. Marino, D. G. Katritsis, P. Caramori, R. Lasevitch, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial Eur. Heart J., January 2, 2009; 30(2): 183 - 191. [Abstract] [Full Text] [PDF]

				C. S. Hollenbeak, C. P. Gorton, Y. P. Tabak, J. L. Jones, A. Milstein, and R. S. Johannes Reductions in Mortality Associated With Intensive Public Reporting of Hospital Outcomes American Journal of Medical Quality, July 1, 2008; 23(4): 279 - 286. [Abstract] [PDF]

				B. R. Shah, J. E. Hux, and P. C. Austin Diabetes Is Not Treated as a Coronary Artery Disease Risk Equivalent Diabetes Care, February 1, 2007; 30(2): 381 - 383. [Full Text] [PDF]

				A. Schomig, G. Ndrepepa, and A. Kastrati Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction Eur. Heart J., August 2, 2006; 27(16): 1900 - 1907. [Abstract] [Full Text] [PDF]

				A. Schomig, J. Mehilli, D. Antoniucci, G. Ndrepepa, C. Markwardt, F. Di Pede, S. G. Nekolla, K. Schlotterbeck, H. Schuhlen, J. Pache, et al. Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset: A Randomized Controlled Trial JAMA, June 15, 2005; 293(23): 2865 - 2872. [Abstract] [Full Text] [PDF]

				D. T. Ko, M. Mamdani, and D. A. Alter Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox JAMA, April 21, 2004; 291(15): 1864 - 1870. [Abstract] [Full Text] [PDF]

				A. Kastrati, J. Mehilli, S. Nekolla, H. Bollwein, S. Martinoff, J. Pache, H. Schuhlen, M. Seyfarth, M. Gawaz, F.-J. Neumann, et al. A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy J. Am. Coll. Cardiol., March 3, 2004; 43(5): 734 - 741. [Abstract] [Full Text] [PDF]

				M. Cohen, G. F. Gensini, F. Maritz, E. P. Gurfinkel, K. Huber, A. Timerman, M. Krzeminska-Pakula, N. Danchin, H. D. White, J. Santopinto, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1348 - 1356. [Abstract] [Full Text] [PDF]